Literature DB >> 23856419

Pathogenesis of mitral valve disease in mucopolysaccharidosis VII dogs.

Paul W Bigg1, Guilherme Baldo, Meg M Sleeper, Patricia A O'Donnell, Hanqing Bai, Venkata R P Rokkam, Yuli Liu, Susan Wu, Roberto Giugliani, Margret L Casal, Mark E Haskins, Katherine P Ponder.   

Abstract

Mucopolysaccharidosis VII (MPS VII) is due to the deficient activity of β-glucuronidase (GUSB) and results in the accumulation of glycosaminoglycans (GAGs) in lysosomes and multisystemic disease with cardiovascular manifestations. The goal here was to determine the pathogenesis of mitral valve (MV) disease in MPS VII dogs. Untreated MPS VII dogs had a marked reduction in the histochemical signal for structurally-intact collagen in the MV at 6 months of age, when mitral regurgitation had developed. Electron microscopy demonstrated that collagen fibrils were of normal diameter, but failed to align into large parallel arrays. mRNA analysis demonstrated a modest reduction in the expression of genes that encode collagen or collagen-associated proteins such as the proteoglycan decorin which helps collagen fibrils assemble, and a marked increase for genes that encode proteases such as cathepsins. Indeed, enzyme activity for cathepsin B (CtsB) was 19-fold normal. MPS VII dogs that received neonatal intravenous injection of a gamma retroviral vector had an improved signal for structurally-intact collagen, and reduced CtsB activity relative to that seen in untreated MPS VII dogs. We conclude that MR in untreated MPS VII dogs was likely due to abnormalities in MV collagen structure. This could be due to upregulation of enzymes that degrade collagen or collagen-associated proteins, to the accumulation of GAGs that compete with proteoglycans such as decorin for binding to collagen, or to other causes. Further delineation of the etiology of abnormal collagen structure may lead to treatments that improve biomechanical properties of the MV and other tissues.
© 2013.

Entities:  

Keywords:  CT; Cathepsin; Ccl; Collagen; Cts; DTT; Dithiothreitol; Dog; ECM; EDTA; EM; ERT; GAG; GUSB; Glycosaminoglycan; HGF; HSCT; IDUA; IV; Il; Interleukin; Intravenous; Lysosomal storage disease; MMP; MPS; MR; MV; Mitral regurgitation; Mucopolysaccharidosis; NIH; National Institutes of Health; OMIM; Online Mendelian Inheritance in Man; Osm; RLU; RT; RV; SLRP; TNF; Tlr4; Toll-like receptor 4; Z-Phe-Arg-AMC; benzyloxycarbonyl-l-phenylalanyl-l-arginine-7-amido-4-methylcoumarin; chemokine (C–C motif) ligand; chordae tendineae; electron microscopy; enzyme replacement therapy; ethylenediaminetetraacetic acid; extracellular matrix; hematopoietic stem cell transplantation; hepatocyte growth factor; matrix metalloproteinase; mitral regurgitation; mitral valve; oncostatin M; red light units; retroviral vector; reverse-transcription; small leucine-rich proteoglycan; tumor necrosis factor-α; α-l-iduronidase; β-glucuronidase

Mesh:

Substances:

Year:  2013        PMID: 23856419      PMCID: PMC3800211          DOI: 10.1016/j.ymgme.2013.06.013

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  44 in total

1.  Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves.

Authors:  E Rabkin; M Aikawa; J R Stone; Y Fukumoto; P Libby; F J Schoen
Journal:  Circulation       Date:  2001-11-20       Impact factor: 29.690

2.  Large proteoglycan complexes and disturbed collagen architecture in the corneal extracellular matrix of mucopolysaccharidosis type VII (Sly syndrome).

Authors:  Robert D Young; Petra Liskova; Christian Pinali; Barbara P Palka; Michalis Palos; Katerina Jirsova; Enkela Hrdlickova; Marketa Tesarova; Milan Elleder; Jiri Zeman; Keith M Meek; Carlo Knupp; Andrew J Quantock
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-24       Impact factor: 4.799

3.  Cathepsin B activity regulation. Heparin-like glycosaminogylcans protect human cathepsin B from alkaline pH-induced inactivation.

Authors:  P C Almeida; I L Nantes; J R Chagas; C C Rizzi; A Faljoni-Alario; E Carmona; L Juliano; H B Nader; I L Tersariol
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

4.  Effect of neonatal gene therapy on lumbar spine disease in mucopolysaccharidosis VII dogs.

Authors:  Lachlan J Smith; John T Martin; Patricia O'Donnell; Ping Wang; Dawn M Elliott; Mark E Haskins; Katherine P Ponder
Journal:  Mol Genet Metab       Date:  2012-03-29       Impact factor: 4.797

5.  Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs.

Authors:  Katherine Parker Ponder; John R Melniczek; Lingfei Xu; Margaret A Weil; Thomas M O'Malley; Patricia A O'Donnell; Van W Knox; Gustavo D Aguirre; Hamutal Mazrier; N Matthew Ellinwood; Meg Sleeper; Albert M Maguire; Susan W Volk; Robert L Mango; Jean Zweigle; John H Wolfe; Mark E Haskins
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-13       Impact factor: 11.205

6.  Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses.

Authors:  Calogera M Simonaro; Yi Ge; Efrat Eliyahu; Xingxuan He; Karl J Jepsen; Edward H Schuchman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

7.  Characterization of surgical procedures in patients with mucopolysaccharidosis type I: findings from the MPS I Registry.

Authors:  Pamela Arn; J Edmond Wraith; Lisa Underhill
Journal:  J Pediatr       Date:  2009-02-12       Impact factor: 4.406

8.  Gene therapy ameliorates cardiovascular disease in dogs with mucopolysaccharidosis VII.

Authors:  M M Sleeper; B Fornasari; N M Ellinwood; M A Weil; J Melniczek; T M O'Malley; C D Sammarco; L Xu; K P Ponder; M E Haskins
Journal:  Circulation       Date:  2004-08-02       Impact factor: 29.690

9.  Microarray identifies extensive downregulation of noncollagen extracellular matrix and profibrotic growth factor genes in chronic isolated mitral regurgitation in the dog.

Authors:  Junying Zheng; Yuanwen Chen; Betty Pat; Louis A Dell'italia; Michael Tillson; A Ray Dillon; Pamela C Powell; Ke Shi; Neil Shah; Thomas Denney; Ahsan Husain; Louis J Dell'Italia
Journal:  Circulation       Date:  2009-04-06       Impact factor: 29.690

10.  Early neurodegeneration progresses independently of microglial activation by heparan sulfate in the brain of mucopolysaccharidosis IIIB mice.

Authors:  Jérôme Ausseil; Nathalie Desmaris; Stéphanie Bigou; Ruben Attali; Sébastien Corbineau; Sandrine Vitry; Mathieu Parent; David Cheillan; Maria Fuller; Irène Maire; Marie-Thérèse Vanier; Jean-Michel Heard
Journal:  PLoS One       Date:  2008-05-28       Impact factor: 3.240

View more
  11 in total

1.  Cardiovascular Histopathology of a 11-Year Old with Mucopolysaccharidosis VII Demonstrates Fibrosis, Macrophage Infiltration, and Arterial Luminal Stenosis.

Authors:  Valerie Lew; Louis Pena; Robert Edwards; Raymond Y Wang
Journal:  JIMD Rep       Date:  2017-07-13

2.  Network Analysis Reveals Proteins Associated with Aortic Dilatation in Mucopolysaccharidoses.

Authors:  Thiago Corrêa; Bruno César Feltes; Esteban Alberto Gonzalez; Guilherme Baldo; Ursula Matte
Journal:  Interdiscip Sci       Date:  2021-01-21       Impact factor: 2.233

Review 3.  Enzyme replacement therapy for mucopolysaccharidoses; past, present, and future.

Authors:  Hui Hsuan Chen; Kazuki Sawamoto; Robert W Mason; Hironori Kobayashi; Seiji Yamaguchi; Yasuyuki Suzuki; Kenji Orii; Tadao Orii; Shunji Tomatsu
Journal:  J Hum Genet       Date:  2019-08-27       Impact factor: 3.172

4.  Neonatal nonviral gene editing with the CRISPR/Cas9 system improves some cardiovascular, respiratory, and bone disease features of the mucopolysaccharidosis I phenotype in mice.

Authors:  Roselena Silvestri Schuh; Esteban Alberto Gonzalez; Angela Maria Vicente Tavares; Bruna Gazzi Seolin; Lais de Souza Elias; Luisa Natalia Pimentel Vera; Francyne Kubaski; Edina Poletto; Roberto Giugliani; Helder Ferreira Teixeira; Ursula Matte; Guilherme Baldo
Journal:  Gene Ther       Date:  2019-12-11       Impact factor: 5.250

5.  The Murine Model of Mucopolysaccharidosis IIIB Develops Cardiopathies over Time Leading to Heart Failure.

Authors:  Gabriele Giacomo Schiattarella; Giuliana Cerulo; Valeria De Pasquale; Pasquale Cocchiaro; Orlando Paciello; Luigi Avallone; Maria Paola Belfiore; Francesca Iacobellis; Daniele Di Napoli; Fabio Magliulo; Cinzia Perrino; Bruno Trimarco; Giovanni Esposito; Paola Di Natale; Luigi Michele Pavone
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

6.  TGF-ß Regulates Cathepsin Activation during Normal and Pathogenic Development.

Authors:  Heather Flanagan-Steet; Courtney Christian; Po-Nien Lu; Megan Aarnio-Peterson; Laura Sanman; Stephanie Archer-Hartmann; Parastoo Azadi; Matthew Bogyo; Richard A Steet
Journal:  Cell Rep       Date:  2018-03-13       Impact factor: 9.423

Review 7.  Cathepsins in the Pathophysiology of Mucopolysaccharidoses: New Perspectives for Therapy.

Authors:  Valeria De Pasquale; Anna Moles; Luigi Michele Pavone
Journal:  Cells       Date:  2020-04-15       Impact factor: 6.600

8.  Dysostosis in mucopolysaccharidosis type 2: A case of longitudinal follow up and literature review.

Authors:  Tomoaki Sasaki; Miki Ogata; Aya Kajihama; Kouichi Nakau; Atsutaka Okizaki
Journal:  Radiol Case Rep       Date:  2021-01-08

9.  Electrophysiological and Histological Characterization of Rod-Cone Retinal Degeneration and Microglia Activation in a Mouse Model of Mucopolysaccharidosis Type IIIB.

Authors:  Dennis Y Tse; Parisa Lotfi; David L Simons; Marco Sardiello; Samuel M Wu
Journal:  Sci Rep       Date:  2015-11-26       Impact factor: 4.379

10.  Inappropriate cathepsin K secretion promotes its enzymatic activation driving heart and valve malformation.

Authors:  Po-Nien Lu; Trevor Moreland; Courtney J Christian; Troy C Lund; Richard A Steet; Heather Flanagan-Steet
Journal:  JCI Insight       Date:  2020-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.